BioAtla, Inc. financial data

Symbol
BCAB on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
11085 Torreyana Road, San Diego, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 28, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 374 % -27.4%
Debt-to-equity 130 % +178%
Return On Equity -236 % -113%
Return On Assets -102 % -35.9%

Shares

Label TTM Value / Value Unit Change %
Common Stock, Shares, Outstanding 58.1M shares +20.8%
Entity Public Float 59.9M USD -34.2%
Common Stock, Value, Issued 6K USD +20%
Weighted Average Number of Shares Outstanding, Basic 48.6M shares +1.67%
Weighted Average Number of Shares Outstanding, Diluted 48.6M shares +1.67%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD
Research and Development Expense 63.1M USD -39.2%
General and Administrative Expense 21.8M USD -15.8%
Operating Income (Loss) -73.9M USD +43%
Net Income (Loss) Attributable to Parent -69.8M USD +43.5%
Earnings Per Share, Basic -1.44 USD/shares +44.2%
Earnings Per Share, Diluted -1.44 USD/shares +44.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 49M USD -56%
Assets, Current 51.2M USD -56%
Property, Plant and Equipment, Net 678K USD -57.7%
Operating Lease, Right-of-Use Asset 512K USD -65.8%
Other Assets, Noncurrent 0 USD -100%
Assets 52.4M USD -56.2%
Accounts Payable, Current 1.9M USD -50.2%
Liabilities, Current 14.5M USD -48.7%
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 38.2M USD -22.1%
Retained Earnings (Accumulated Deficit) -486M USD -16.8%
Stockholders' Equity Attributable to Parent 14.3M USD -79.8%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 14.3M USD -79.8%
Liabilities and Equity 52.4M USD -56.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -30.8M USD -36.1%
Net Cash Provided by (Used in) Financing Activities -13K USD +88.8%
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 350M shares 0%
Common Stock, Shares, Issued 58.1M shares +20.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 49M USD -56%
Deferred Tax Assets, Valuation Allowance 103M USD +19.9%
Deferred Tax Assets, Gross 103M USD +19.3%
Operating Lease, Liability 836K USD -66%
Lessee, Operating Lease, Liability, to be Paid 845K USD -66.6%
Property, Plant and Equipment, Gross 7.68M USD 0%
Operating Lease, Liability, Current 836K USD -48.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 845K USD -49.9%
Lessee, Operating Lease, Liability, to be Paid, Year One 425K USD +3.41%
Operating Lease, Weighted Average Discount Rate, Percent 0.04 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 9K USD -87.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 845K USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 33.8M USD +35%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 200M shares 0%
Unrecognized Tax Benefits 4.58M USD +27.2%
Operating Lease, Payments 1.69M USD +12.3%
Additional Paid in Capital 500M USD +2.75%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 240K USD -18.1%
Deferred Tax Assets, Net of Valuation Allowance 183K USD -66.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%